Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT06319885
Recruiting Not applicable

Text Messaging to Reduce High-risk Alcohol Use Among Older Adults

NCT06319885 · tracked via the Priya Life Science Denmark tracker
Sponsor
University of Southern Denmark
Phase
Not applicable
Started
2024-04-15
Last updated
2025-04-02

Condition(s) studied

Hazardous Alcohol Use

Investigational drug(s) / intervention(s)

Text messaging

Text messaging: Participants receive text messages related to their alcohol consumption.

Study summary

High-risk drinking is very prevalent among Danes aged 55+. It poses a serious risk to health and independent living, burdening health care systems and family members. Measures to reduce high-risk alcohol use in this growing group at need are urgently needed. A recent small study from the US shows that text messaging reduces high-risk alcohol intake in older adults. The investigators will conduct a pilot study with the same intervention in Denmark, with adaptations to language and culture. The pilot study will investigate among Danish older adults whether text messaging is well-accepted by participants and feasible in terms of reducing 1) high-risk drinking and 2) commonly accompanying problems with daily functioning, social relationships, and mental and physical health. The pilot-trial will include n=60 adults aged 55-80 years who will receive alcohol-related text messages (within a secure app for data protection purposes) over 12 weeks. Assessments will include a baseline assessment and a post-assessment.

Eligibility

Sex
ALL
Min age
55 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * consumption of \> 10 standard drinks á 12 gram ethanol per week (i.e., high-risk alcohol use defined by the Danish Health Authority) in the past four weeks * desire to reduce drinking * age 55 to 80 years * mobile phone ownership and willingness to receive and respond to text messages * fluency in Danish. Exclusion Criteria: * drinking more than 53 standard drinks per week in the last four weeks * past 12 month alcohol withdrawal symptoms or lifetime history of serious withdrawal symptoms (e.g., seizures) * score above 12 on the Short alcohol withdrawal scale; SAWS * possible drug dependence (i.e., use of illegal drugs or psychotropic medication taken without prescription more than once a month) * indication of serious psychiatric illness (lifetime diagnosis of psychosis or bipolar disorder, inpatient treatment or medication for these, recent suicidality) * current alcohol/drug abuse treatment or a desire to start alcohol/drug abuse treatment during the study * medical condition that requires abstinence from alcohol * wish to achieve abstinence (applied to secure a focus on reduction) * lack of understanding of study protocol or reading difficulty as evidenced by a score of less than 7 out of 10 on the consent form quiz.

Primary outcome measure(s)

  • High-risk alcohol use (yes/no) — Assessed at 12 weeks after baseline, alcohol use through the past seven days
    Drinking over 120 gram ethanol in seven days (determined by outcomes 4 \& 5 )

Trial sites (1)

FacilityCityRegionStatus
University of Southern Denmark, Department of Psychology Odense Southern Denmark Recruiting

More University of Southern Denmark trials in Denmark

Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial) Recruiting
The Bloom Study - a Safe and Healthy Start in Life Recruiting
The Effect of Long-term Daily Stimulation of the Brain With Pulsed Electromagnetic Fields on Parkinsons Disease Recruiting
Chest Radiography Versus Ultra-Low-Dose Chest Computed Tomography in Adults in the Emergency Department Recruiting
The ECHO Study: Compassion-focused Therapy for Young Voice Hearers and Their Caregivers Starting soon

Other trials for the same condition

The 15-Mental Project: Implementation and Evaluation of the 15-Mental in a Mental Health Hospital Setting Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06319885 on ClinicalTrials.gov ↗ ← All trials in Denmark